Home › Cystic Fibrosis › NCT04793867

Regional Phenotyping of CF and Non-CF Bronchiectasis

Regional Phenotyping of Cystic Fibrosis Lung Disease and Non-CF Bronchiectasis

Who can join

Ages 5 to 100 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* CF Patients: Diagnosis of CF based on sweat chloride \>60 mMol/l
* Presence of two disease causing CFTR mutations, or end organ manifestations of disease.
* Age minimum 5 years.
* Care provided by the CCHMC CF Care Center or other regional CF Care Centers if required to achieve recruitment goals.

Exclusion Criteria:

* Patients meeting standard MRI exclusions criteria (non-MRI-compatible metal implants, claustrophobia, etc.)
* Pregnancy or lactation.

Inclusion Criteria of Healthy Subjects:

* Subjects 5 years of age and older with no known history of cardiopulmonary disease.

Exclusion Criteria of Healthy Subjects:

* Patients meeting standard MRI exclusions criteria (non-MRI-compatible metal implants, claustrophobia, etc.)
* Pregnancy or lactation.

About the study

The Investigators propose to study pediatric subjects who are diagnosed with cystic fibrosis (CF) and patients with non-CF bronchiectasis, with the goal of developing markers of CF lung disease severity, progression, and therapy response. The Investigator's central hypothesis is that image-based markers can forecast pathophysiology prior to spirometric changes.

What is being tested

• Xenon (drug)

Sponsor: Children's Hospital Medical Center, Cincinnati · Participants: 100 · Started: Feb 8, 2021

Contact the study team

• Penny A New, BBA · Phone: 513-332-7931
• Carrie Stevens, BS · Phone: 513-636-9973

Official record on ClinicalTrials.gov — NCT04793867

Locations in the U.S.

Conditions

• Cystic Fibrosis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.